102 related articles for article (PubMed ID: 7488410)
21. [Phase II study of combination chemotherapy with epirubicin, cyclophosphamide and ftorafur in metastatic breast cancer].
Shinagawa K; Ogawa M; Horikoshi N; Inoue K; Mukaiyama T; Fukutani H; Tabata M; Hirano A; Mizunuma N
Gan To Kagaku Ryoho; 1988 Dec; 15(12):3277-81. PubMed ID: 3143311
[TBL] [Abstract][Full Text] [Related]
22. Phase III study of intravenous vinorelbine in combination with epirubicin versus epirubicin alone in patients with advanced breast cancer: a Scandinavian Breast Group Trial (SBG9403).
Ejlertsen B; Mouridsen HT; Langkjer ST; Andersen J; Sjöström J; Kjaer M;
J Clin Oncol; 2004 Jun; 22(12):2313-20. PubMed ID: 15197192
[TBL] [Abstract][Full Text] [Related]
23. Epirubicin and ifosfamide in patients with refractory breast cancer and other metastatic solid tumours.
Hoffmann W; Weidmann B; Migeod F; Könner J; Seeber S
Cancer Chemother Pharmacol; 1990; 26 Suppl():S69-70. PubMed ID: 2347053
[TBL] [Abstract][Full Text] [Related]
24. Epirubicin-based chemotherapy in metastatic breast cancer patients: role of dose-intensity and duration of treatment.
French Epirubicin Study Group
J Clin Oncol; 2000 Sep; 18(17):3115-24. PubMed ID: 10963640
[TBL] [Abstract][Full Text] [Related]
25. Randomized, phase III trial of sequential epirubicin and docetaxel versus epirubicin alone in postmenopausal patients with node-positive breast cancer.
Coombes RC; Bliss JM; Espie M; Erdkamp F; Wals J; Tres A; Marty M; Coleman RE; Tubiana-Mathieu N; den Boer MO; Wardley A; Kilburn LS; Cooper D; Thomas MW; Reise JA; Wilkinson K; Hupperets P
J Clin Oncol; 2011 Aug; 29(24):3247-54. PubMed ID: 21768453
[TBL] [Abstract][Full Text] [Related]
26. Interim Analysis of a Phase II study of epirubicin and paclitaxel as first-line therapy in patients with metastatic breast cancer.
Luck HJ; Thomssen C; duBois A; Lisboa BW; Untch M; Kuhnle H; Konecny G; Janicke F; Meerpohl HG; Lindner C; Hecker D; Diergarten K
Semin Oncol; 1996 Feb; 23(1 Suppl 1):33-6. PubMed ID: 8629034
[TBL] [Abstract][Full Text] [Related]
27. Epirubicin-containing high-dose chemotherapy followed by autologous hematopoietic progenitor cell transfusion for patients with chemotherapy-sensitive metastatic breast cancer: results of 5-year follow-up.
Ito Y; Mukaiyama T; Ogawa M; Mizunuma N; Takahashi S; Aiba K; Horikoshi N
Cancer Chemother Pharmacol; 1999; 43(1):8-12. PubMed ID: 9923535
[TBL] [Abstract][Full Text] [Related]
28. Phase II trial of high-dose epirubicin and cyclophosphamide in advanced breast cancer.
Scinto AF; Cercato MC; Botti C; Tonachella R; Ferraresi V; Del Bianco S; Sacchi I; Cognetti F
Eur J Cancer; 1994; 30A(9):1285-8. PubMed ID: 7999414
[TBL] [Abstract][Full Text] [Related]
29. Lonidamine plus cyclophosphamide in the treatment of adanced non-small cell lung cancer in the elderly: a phase II study.
Salvati F; Antilli A; Cruciani AR; Lombardi A; Mugnaini L; Nunziati F; Perrone N; Portalone L; Signora M
Tumori; 1995; 81(1):48-51. PubMed ID: 7754542
[TBL] [Abstract][Full Text] [Related]
30. Neoadjuvant chemotherapy of breast cancer with pirarubicin versus epirubicin in combination with cyclophosphamide and docetaxel.
Gu X; Jia S; Wei W; Zhang WH
Tumour Biol; 2015 Jul; 36(7):5529-35. PubMed ID: 25682286
[TBL] [Abstract][Full Text] [Related]
31. Revertant and potentiating activity of lonidamine in patients with ovarian cancer previously treated with platinum.
De Lena M; Lorusso V; Bottalico C; Brandi M; De Mitrio A; Catino A; Guida M; Latorre A; Leone B; Vallejo C; Gargano G
J Clin Oncol; 1997 Oct; 15(10):3208-13. PubMed ID: 9336357
[TBL] [Abstract][Full Text] [Related]
32. Phase I studies of combined paclitaxel/epirubicin and paclitaxel/epirubicin/cyclophosphamide in patients with metastatic offast cancer: the French experience.
Catimel G; Spielmann M; Dieras V; Tubiana-Hulin M; Bonneterre J; Pouillart P; Kayitalire L; Guastalla JP; Graffand N; Garet F; Dumortier A; Pellae-Cosset B
Semin Oncol; 1997 Feb; 24(1 Suppl 3):S8-12. PubMed ID: 9071333
[TBL] [Abstract][Full Text] [Related]
33. Phase II study of high-dose epirubicin, lonidamine, alpha 2b interferon in advanced breast cancer.
Iaffaioli RV; Tortoriello A; Facchini G; Santangelo M; Bucci L; Fei L; Di Martino N; Mantovani G; Caponigro F
Breast Cancer Res Treat; 1995 Sep; 35(3):243-8. PubMed ID: 7579494
[TBL] [Abstract][Full Text] [Related]
34. Disease-free survival advantage of weekly epirubicin plus tamoxifen versus tamoxifen alone as adjuvant treatment of operable, node-positive, elderly breast cancer patients: 6-year follow-up results of the French adjuvant study group 08 trial.
Fargeot P; Bonneterre J; Roché H; Lortholary A; Campone M; Van Praagh I; Monnier A; Namer M; Schraub S; Barats JC; Guastalla JP; Goudier MJ; Chapelle-Marcillac I
J Clin Oncol; 2004 Dec; 22(23):4622-30. PubMed ID: 15505276
[TBL] [Abstract][Full Text] [Related]
35. Epirubicin-vinorelbine vs FEC100 for node-positive, early breast cancer: French Adjuvant Study Group 09 trial.
Kerbrat P; Roché H; Bonneterre J; Veyret C; Lortholary A; Monnier A; Fumoleau P; Fargeot P; Namer M; Chollet P; Goudier MJ; Audhuy B; Simon H; Montcuquet P; Eymard JC; Walter S; Clavère P; Guastalla JP;
Br J Cancer; 2007 Jun; 96(11):1633-8. PubMed ID: 17505516
[TBL] [Abstract][Full Text] [Related]
36. First-line treatment with epirubicin and vinorelbine in metastatic breast cancer.
Vici P; Colucci G; Gebbia V; Amodio A; Giotta F; Belli F; Conti F; Gebbia N; Pezzella G; Valerio MR; Brandi M; Pisconti S; Durini E; Giannarelli D; Lopez M
J Clin Oncol; 2002 Jun; 20(11):2689-94. PubMed ID: 12039931
[TBL] [Abstract][Full Text] [Related]
37. Neoadjuvant chemotherapy with or without anthracyclines in the presence of dual HER2 blockade for HER2-positive breast cancer (TRAIN-2): a multicentre, open-label, randomised, phase 3 trial.
van Ramshorst MS; van der Voort A; van Werkhoven ED; Mandjes IA; Kemper I; Dezentjé VO; Oving IM; Honkoop AH; Tick LW; van de Wouw AJ; Mandigers CM; van Warmerdam LJ; Wesseling J; Vrancken Peeters MT; Linn SC; Sonke GS;
Lancet Oncol; 2018 Dec; 19(12):1630-1640. PubMed ID: 30413379
[TBL] [Abstract][Full Text] [Related]
38. Laevofolinic acid, 5-fluorouracil, cyclophosphamide and escalating doses of epirubicin with granulocyte colony-stimulating factor support in locally advanced and/or metastatic breast carcinoma: a phase I-II study of the Southern Italy Oncology Group (GOIM).
Colucci G; Romito S; Gebbia V; Pacilio G; Giotta F; Testa A; Pezzella G; Durini E; Agostara B; Cariello S
Br J Cancer; 1995 Nov; 72(5):1245-50. PubMed ID: 7577476
[TBL] [Abstract][Full Text] [Related]
39. Influence of treatment schedule on toxicity and efficacy of cyclophosphamide, epirubicin, and fluorouracil in metastatic breast cancer: a randomized trial comparing weekly and every-4-week administration.
Blomqvist C; Elomaa I; Rissanen P; Hietanen P; Nevasaari K; Helle L
J Clin Oncol; 1993 Mar; 11(3):467-73. PubMed ID: 8445422
[TBL] [Abstract][Full Text] [Related]
40. A prospective randomized phase III trial comparing combination chemotherapy with cyclophosphamide, fluorouracil, and either doxorubicin or epirubicin. French Epirubicin Study Group.
J Clin Oncol; 1988 Apr; 6(4):679-88. PubMed ID: 2895801
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
